US › Healthcare

CNS Pharmaceuticals Inc (CNSP)

US · Healthcare · Biotechnology

$5.12-6.91%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-2.6M

EPS

$-0.38

EPS estimate

$-0.24

EPS came in at -0.38 against a street estimate of -0.24 — a miss of 58.3%.

Key statistics

Market cap

$8.0M

Forward P/E

0.0

P/B

0.46

Book value

$12.45

EPS (TTM)

$-14.85

52-week high

$10.59

52-week low

$1.90

50-day MA

$5.47

200-day MA

$4.80

Beta

1.00

Analyst view

Analysts rate CNS Pharmaceuticals Inc a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $10.00.

Shareholding

Insiders

0.95%

Institutions

21.25%

Largest institutional holders

Fund	Stake
Stonepine Capital Management Llc	4.17%
Ikarian Capital, LLC	3.14%
Geode Capital Management, LLC	1.59%
BOOTHBAY FUND MANAGEMENT, LLC	0.93%
Tower Research Capital LLC	0.09%
UBS Group AG	0.05%
BARRETT & COMPANY, INC.	0.00%
Mccormack Advisors International	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for CNS Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.